基线卒中风险与双联抗血小板治疗疗效:POINT 试验的事后分析
该研究为 POINT 试验的非计划二次分析,共纳入 4841 例短暂性脑缺血发作或轻型缺血性卒中患者。结果显示,SPI-II 评分高危(>3)者接受双联抗血小板治疗的缺血性卒中绝对风险降低更高(2.80% 对 0.76%),但大出血绝对风险增加也更高(0.84% 对 0.30%)。
要点
- SPI-II 评分>3 分者缺血性卒中风险较低评分者升高(HR 1.84,95%CI 1.44-2.35)。
- 双联抗血小板治疗的相对疗效在 SPI-II 分层间相似(交互作用 P=0.31)。
- 高危 SPI-II 分层者接受双联抗血小板治疗的缺血性卒中绝对获益更大,需治疗人数为 31。
核心结论
- 按基线卒中风险分层可识别出从双联抗血小板治疗中获得更大绝对获益的患者亚组。
研究设计与样本
- POINT 试验的非计划二次分析,共纳入 4841 例参与者,其中 2400 例接受短期双联抗血小板治疗,2430 例接受阿司匹林加安慰剂。
主要发现
- 二分类 SPI-II 评分与缺血性卒中风险相关,而 CHA2DS2-VASc 评分与缺血性卒中风险无关(P=0.18)。
- SPI-II 评分高危(>3)者较低危者缺血性卒中风险升高(HR 1.84,95%CI 1.44-2.35;P<0.001)。
- SPI-II 评分高危(>3)者较大出血风险数值上升高但未达统计学显著(HR 1.80,95%CI 0.90-3.57;P=0.10)。
- 双联抗血小板治疗的相对风险降低在 SPI-II 分层间相似(交互作用 P=0.31)。
- 高危 SPI-II 分层较低危分层:双联抗血小板治疗对比阿司匹林的缺血性卒中绝对风险降低为 2.80% 对 0.76%,需治疗人数为 31 对 131;大出血绝对风险增加为 0.84% 对 0.30%,需伤害人数为 119 对 331。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-risk transient ischemic attacks and minor ischemic strokes are followed by a variable risk of ischemic stroke. We aimed to determine how baseline stroke risk modified the efficacy of clopidogrel-aspirin (referred to here as dual-antiplatelet therapy [DAPT]) for transient ischemic attack and minor ischemic stroke. METHODS: We performed an unplanned secondary analysis of the POINT trial (Platelet-Oriented Inhibition in New Transient Ischemic Attack and Minor Ischemic Stroke). We first evaluated the associations of the CHA2DS2-VASc and stroke prognosis instrument II (SPI-II) scores with the risk of incident ischemic stroke and major hemorrhage (intracranial hemorrhage or major systemic hemorrhage). We then tested for heterogeneity of the relative and absolute treatment effect of DAPT relative to aspirin across low- and high-risk patient subgroups. RESULTS: A total of 4841 trial participants were included in this analysis, with 2400 participants assigned to treatment with short-term DAPT and 2430 participants to treatment with aspirin and placebo. The dichotomized SPI-II score, but not the CHA2DS2-VASc score (P=0.18), was associated with the risk of incident ischemic stroke. A high-risk SPI-II score (>3) was associated with greater risk of incident ischemic stroke (hazard ratio of incident ischemic stroke relative to low-risk SPI-II score of 1.84 [95% CI, 1.44-2.35]; P<0.001) and numerically greater risk of major hemorrhage though not meeting statistical significance (hazard ratio, 1.80 [95% CI, 0.90-3.57]; P=0.10). The relative risk reduction with DAPT was similar across SPI-II strata (Pinteraction=0.31). The absolute risk reduction for ischemic stroke with DAPT compared with aspirin was nearly 4-fold higher (2.80% versus 0.76%; number needed to treat, 31 versus 131) in the high-risk SPI-II stratum relative to the low-risk stratum. The absolute risk increase for major hemorrhage with DAPT compared with aspirin was 3-fold higher (0.84% versus 0.30%; number needed to harm, 119 versus 331) in the high-risk SPI-II stratum relative to the low-risk stratum. CONCLUSIONS: Stratification by baseline stroke risk identifies a patient subgroup that derives greater absolute benefit from treatment with DAPT. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00991029.
引用
- Daghlas I, Johnston SC, Easton JD, et al. Baseline Stroke Risk and Efficacy of Dual-Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial. Stroke. 2024. PMID: 38174567. doi:10.1161/STROKEAHA.123.044927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。